Galecto Inc.
http://www.galecto.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Galecto Inc.
PureTech Takes On Roche With Improved IPF Drug
The firm’s lead candidate has shown strong tolerability in an early-stage trial for idiopathic pulmonary fibrosis, sparking hopes for registration-enabling studies and a streamlined development plan.
Finance Watch: Four New VC Funds Provide $1.3bn For Biotech Start-Ups
Private Company Edition: Newpath Partners’ second fund totals $350m, Merck KGaA committed €600m to M Ventures, Eir Ventures raised €122.3m and Breakout Ventures has $112.5m. Recent financings were led by SOTIO ($317.5m), Odyssey ($218m), Avistone ($200m) and Acepodia ($109m).
Clover, Chengda IPOs Add To $1.2bn Raised By Chinese Bioventures
The listings of two vaccine manufacturers and fundraisings by seven other biopharma ventures generate around $1.2bn in new financing for Chinese companies focusing on a broad variety of therapeutic areas and indicating continued investor interest.
Finance Watch: Have Biopharma IPOs Hit Their Limit?
Public Company Edition: Three companies postponed or withdrew their offerings, but drug developers continue to pursue IPOs. Also, Biocon, BMS and Epizyme raised money through new debt, Five Prime capitalized on positive data and Synthetic Biologic engaged a strategic advisor.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Drug Delivery
- Other Names / Subsidiaries
-
- PharmAkea, Inc.
- Galecto Biotech Inc.